Inherited Bleeding Disorder in Dogs (von Willebrand Disease)
- Occurrence: very rare
- Location of disease: General/Whole body
When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Von Willebrand Syndrome (vWS) is a genetically determined blood coagulation disorder in dogs, characterized by a deficiency or dysfunction of the von Willebrand factor (vWF), a crucial protein for blood coagulation.
BASICS/CAUSES:
The von Willebrand factor is an essential protein in blood plasma that plays a central role in blood coagulation. It helps bring platelets to the site of a vascular injury and forms a bridge between the platelets and the injured vessel wall. The vWF is also important for stabilizing blood coagulation factor VIII, which is also necessary for coagulation. A deficiency or dysfunction of vWF can therefore lead to insufficient hemostasis.
Von Willebrand Syndrome has genetic causes and is often an autosomal dominant hereditary disease, meaning that only one defective gene from one parent is sufficient to pass on the disease. However, there are also recessive forms of the disease. Certain dog breeds are particularly susceptible, including Dobermans, German Shepherds, Golden Retrievers, Labrador Retrievers, Cocker Spaniels, and Shetland Sheepdogs, indicating a genetic predisposition in these populations.
The molecular basis of the disease lies in mutations in the VWF gene, which either reduce the production of the protein or impair its function. The variability of mutation types and their effects on vWF leads to different severities of the disease, ranging from mild to severe.
Das Wichtigste auf einen Blick
Von Willebrand Syndrome (vWS) in dogs is a genetically determined blood coagulation disorder, inherited either as an autosomal dominant or autosomal recessive trait. Certain dog breeds such as Dobermans, Scottish Terriers, and Shetland Sheepdogs are particularly susceptible. Common symptoms include mucosal hemorrhages, bloody stools, blood in the urine, and delayed blood coagulation. Diagnosis involves clinical examinations, specific blood tests to measure the von Willebrand factor (vWF), and genetic analyses. A vWF level below 50% of the normal value is diagnostic for the syndrome. Therapy aims to control Bleeding, with no specific cure available. Desmopressin can help in acute cases but is not always effective. Blood transfusions and fresh frozen plasma can increase vWF levels. Prevention focuses on responsible breeding practices to minimize the spread of the disease. Regular veterinary check-ups and avoiding injury risks are crucial for affected dogs. Research focuses on the genetic basis of the disease, improving diagnostic methods, and developing new therapy strategies, including potential gene therapies. These efforts aim not only to improve the quality of life of affected dogs but also to provide insights into similar diseases in humans.
Ursachen
- Genetically determined, inherited as an autosomal dominant or autosomal recessive trait. Various breeds may be predisposed, including Dobermans, Scottish Terriers, and Shetland Sheepdogs.
Symptoms
The symptoms of Von Willebrand Syndrome vary depending on the severity of the disease and can range from mild to life-threatening Bleeding. Mild cases can be asymptomatic and often go unnoticed until an injury or surgery occurs, revealing an abnormal tendency to bleed.
Common symptoms include persistent or excessive Bleeding after injuries or surgical procedures, spontaneous mucosal hemorrhages such as nosebleeds or bleeding gums, as well as blood in the urine or stool. In severe cases, internal Bleeding can occur, manifesting as weakness, pallor, or swelling.
Particularly noticeable is the prolonged bleeding time with minor injuries or after nail trimming. These can indicate a disturbed blood coagulation and should be medically evaluated by a veterinarian.
Diagnose
The diagnosis of Von Willebrand Syndrome is made through a combination of clinical examinations, specific blood tests, and genetic analyses. A detailed history, including symptoms and possible family medical history, can provide important clues.
A basic test is the measurement of bleeding time, which is prolonged in affected dogs. Furthermore, the concentration of von Willebrand factor in the blood is measured. A vWF level below 50% of the normal value is considered diagnostic for the syndrome. Additional tests, such as ristocetin cofactor activity, which checks the functionality of vWF, can also be performed.
Genetic tests are particularly helpful in identifying carriers of the defective gene, especially in breeding lines known for the disease. These tests enable targeted breeding planning to minimize the spread of the disease.
Therapie
The therapy for Von Willebrand Syndrome aims to control and prevent Bleeding. There is no specific cure, but various therapeutic measures can support coagulation and alleviate symptoms.
In acute cases of Bleeding, treatment with desmopressin (DDAVP) can help stimulate the release of vWF from the body’s storage cells. However, this therapy is not effective in all dogs and depends on the type and severity of the disease.
Blood transfusions or the administration of frozen fresh plasma may be necessary to increase vWF levels and improve clotting, especially before surgical procedures or in cases of severe Bleeding.
Long-term, it is important to minimize the risk of injury and avoid situations that could trigger Bleeding. Regular veterinary check-ups and close cooperation with the veterinarian are crucial to monitor and adjust the dog’s health status.
Prognose und Nachsorge
The prognosis for dogs with Von Willebrand Syndrome largely depends on the severity of the disease and the type of treatment. Dogs with mild vWS can lead a normal life if well-managed and Bleeding is avoided. However, regular veterinary monitoring is essential.
Dogs with more severe forms of the disease who experience frequent or severe Bleeding require more intensive medical care and possibly lifelong treatments to support blood coagulation. In such cases, the quality of life may be impaired, and there is an increased risk of complications during surgeries or injuries.
The genetic nature of the disease makes it important that affected dogs are not used for breeding to prevent the spread of the defective gene in the population.
Prävention
Prevention of Von Willebrand Syndrome primarily focuses on responsible breeding practices. Genetic tests can identify carriers of the defective gene, making it possible to exclude affected animals from breeding. This is particularly important in breeds predisposed to the disease.
For dogs already suffering from vWS, it is crucial to minimize the risk of injury and avoid situations that could trigger Bleeding. This includes dog owners being informed about the disease and taking measures to prevent accidents, such as avoiding rough play or wearing a protective harness instead of a collar.
Regular veterinary check-ups and awareness of the symptoms and risks of Bleeding are crucial for early intervention and maintaining the dog’s health. Close cooperation with a veterinarian experienced in vWS is also important to create an individualized treatment and prevention plan.
Ausblick auf aktuelle Forschung
Research on Von Willebrand Syndrome (vWS) in dogs focuses on the genetic basis of the disease, improving diagnostic methods, and developing new therapy strategies. vWS is a hereditary blood coagulation disorder caused by a deficiency or dysfunction of the von Willebrand factor (vWF), a protein essential for blood coagulation. Genetic research has shown that vWS is caused by mutations in the gene responsible for vWF production. There are different types of the disease, which vary in their genetic basis and severity, further complicating research.
An important aspect of research is the identification of specific genetic mutations that cause vWS in different dog breeds. Through genetic screening and the analysis of DNA samples from affected dogs, scientists have identified mutations associated with the disease. This has led to the development of genetic tests that allow breeders to test dogs for the risk of vWS and thus reduce the spread of the disease.
In addition to genetic aspects, research also focuses on improving diagnostic methods. Traditionally, vWS is diagnosed by blood tests that measure the amount and function of vWF in the blood. Newer approaches include the development of more specific and sensitive tests that enable a more accurate diagnosis. These tests can help identify the disease at an earlier stage, allowing for early intervention and improving the quality of life for affected dogs.
Regarding therapy options, progress is being made in developing new therapeutic approaches. Currently, therapy mainly consists of administering medications that support blood coagulation, as well as avoiding situations that could trigger Bleeding. Future therapy strategies could include gene therapies aimed at correcting the underlying genetic defects and restoring normal vWF production. However, such treatments are still in the experimental stage and are the subject of intensive research.
Research into vWS in dogs is crucial, not only to improve the quality of life of affected animals but also to gain insights into similar diseases in humans. Since vWS is one of the most common hereditary blood coagulation disorders, studying this disease in dogs provides valuable information that could also be transferable to humans. Interdisciplinary exchange between veterinarians, geneticists, and hematologists helps advance research and develop potential therapy approaches for both dogs and humans.